{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T22:46:50Z","timestamp":1773614810176,"version":"3.50.1"},"reference-count":31,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Switzerland"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,3,18]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Postbariatric hypoglycaemia (PBH) is a complex medical condition with a significant impact on patients\u2019 quality of life. The underlying mechanisms remain to be elucidated. We have shown that food ingestion increases IL-1\u03b2 and subsequently stimulates insulin secretion. We therefore hypothesised that overactivation of the IL-1\u03b2 pathway could lead to PBH by promoting excessive insulin secretion after a meal. In a proof-of-concept study, we have shown that acute treatment with the IL-1 receptor antagonist anakinra can attenuate PBH after a single liquid mixed meal. This study aims to validate this therapeutic approach over a longer period of time using the long-acting anti-IL-1\u03b2 antibody canakinumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>In this prospective, randomised, double-blind, placebo-controlled, multicentre trial, we plan to enrol 62 adult patients after bariatric surgery with frequent, postprandial hypoglycaemia (ie, &lt;3.0\u2009mmol\/L and at least five hypoglycaemic episodes per week). Eligible subjects will be randomised to receive either single-dose 150\u2009mg canakinumab (Ilaris, Novartis) subcutaneously (s.c.) or matched placebo (1.0\u2009mL physiologic saline). For 28 days, patients are required to wear a blinded continuous glucose monitoring device (CGMS, Dexcom G6) and use a diary to track their hypoglycaemic episodes. Primary outcomes include health-related quality of life, measured by the SF-36, as well as postprandial hypoglycaemic events (glucose &lt;3.0\u2009mmol\/L). A significant improvement in any one of these outcomes will be considered sufficient to demonstrate the clinical superiority of canakinumab over placebo. Secondary outcomes include patient-oriented measures such as postprandial hypoglycaemic symptoms, hypoglycaemia unawareness, fear of hypoglycaemia, as well as metabolic measures and safety assessments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The trial was approved by the Cantonal Ethics Committee \u2018Ethikkommission Nordwest- und Zentralschweiz\u2019 in January 2022 (#2021\u201302325), as well as by Swissmedic in April 2022 (#701280). Current, approved protocol version 1.3 of 28.03.2023. The study is actively recruiting. Results will be published in a relevant scientific journal and communicated to participants and relevant institutions through dissemination activities. Individual data are accessible on request.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>The study is registered with the<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link>registry (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05401578\">NCT05401578<\/jats:ext-link>) and the Swiss National Clinical Trials Portal (SNCTP) on<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"www.kofam.ch\">www.kofam.ch<\/jats:ext-link>(SNCTP000004838).<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2024-097981","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T06:15:39Z","timestamp":1748326539000},"page":"e097981","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Canakinumab for the treatment of postprandial hypoglycaemia: study protocol for a randomised, placebo-controlled, parallel-group, double-blind, multicentric, superiority trial\u2014the CanpHy study"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05401578","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6905-6235","authenticated-orcid":false,"given":"Matthias","family":"Hepprich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justus","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6610-8431","authenticated-orcid":false,"given":"Marco","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Herzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-7672","authenticated-orcid":false,"given":"Lia","family":"Bally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Donath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"2025052623151376000_15.5.e097981.1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21042"},{"key":"2025052623151376000_15.5.e097981.2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.soard.2014.11.003","article-title":"Hypoglycemia after Roux-En-Y gastric bypass: detection rates of continuous glucose monitoring (CGM) versus mixed meal test","volume":"11","author":"Kefurt","year":"2015","journal-title":"Surg Obes Relat Dis"},{"key":"2025052623151376000_15.5.e097981.3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.soard.2011.11.023","article-title":"Abnormal glucose tolerance testing after gastric bypass","volume":"9","author":"Roslin","year":"2013","journal-title":"Surg Obes Relat Dis"},{"key":"2025052623151376000_15.5.e097981.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.08.047"},{"key":"2025052623151376000_15.5.e097981.5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.soard.2014.11.023","article-title":"Why it matters. A paired editorial for \u201cHypoglycemia after Roux-en-Y gastric bypass: detection rates of continuous glucose monitoring (CGM) versus mixed meal test\u201d","volume":"11","author":"Roslin","year":"2015","journal-title":"Surg Obes Relat Dis"},{"key":"2025052623151376000_15.5.e097981.6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s11695-018-3559-3","article-title":"Health-Related Quality of Life 5 Years After Roux-en-Y Gastric Bypass in Young (18-25 Years) Versus Older (\u2265\u200926 Years) Adults: a Scandinavian Obesity Surgery Registry Study","volume":"29","author":"Dreber","year":"2019","journal-title":"Obes Surg"},{"key":"2025052623151376000_15.5.e097981.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-020-01171-z","article-title":"Patient involvement to inform the design of a clinical trial in postbariatric hypoglycaemia","volume":"20","author":"Hepprich","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"2025052623151376000_15.5.e097981.8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.metabol.2015.10.020","article-title":"Post-prandial hypoglycemia results from a non-glucose-dependent inappropriate insulin secretion in Roux-en-Y gastric bypassed patients","volume":"65","author":"Vaurs","year":"2016","journal-title":"Metab Clin Exp"},{"key":"2025052623151376000_15.5.e097981.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-010-1489-9"},{"key":"2025052623151376000_15.5.e097981.10","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1210\/jc.2016-1143","article-title":"Risk Factors for Spontaneously Self-Reported Postprandial Hypoglycemia After Bariatric Surgery","volume":"101","author":"Nannipieri","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025052623151376000_15.5.e097981.11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0918"},{"key":"2025052623151376000_15.5.e097981.12","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0285","article-title":"Society for Endocrinology guidelines for the diagnosis and management of post-bariatric hypoglycaemia","volume":"13","author":"Hazlehurst","year":"2024","journal-title":"Endocr Connect"},{"key":"2025052623151376000_15.5.e097981.13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13679-022-00482-0","article-title":"Medical Nutrition Therapy and Other Approaches to Management of Post-bariatric Hypoglycemia: A Team-Based Approach","volume":"11","author":"Patience","year":"2022","journal-title":"Curr Obes Rep"},{"key":"2025052623151376000_15.5.e097981.14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.soard.2016.09.025","article-title":"Postprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: an update","volume":"13","author":"\u00d8hrstr\u00f8m","year":"2017","journal-title":"Surg Obes Relat Dis"},{"key":"2025052623151376000_15.5.e097981.15","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-015-0711-5","article-title":"Post-Gastric Bypass Hypoglycemia","volume":"16","author":"Rariy","year":"2016","journal-title":"Curr Diab Rep"},{"key":"2025052623151376000_15.5.e097981.16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200215318"},{"key":"2025052623151376000_15.5.e097981.17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-024-06306-1","article-title":"Targeting the NLRP3 inflammasome-IL-1\u03b2 pathway in type 2 diabetes and obesity","volume":"68","author":"Meier","year":"2025","journal-title":"Diabetologia"},{"key":"2025052623151376000_15.5.e097981.18","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3659"},{"key":"2025052623151376000_15.5.e097981.19","doi-asserted-by":"publisher","DOI":"10.1038\/nri2925"},{"key":"2025052623151376000_15.5.e097981.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.02.013"},{"key":"2025052623151376000_15.5.e097981.21","unstructured":"Compendium.ch. fachinformation ilaris (canakinumab). Available: https:\/\/compendium.ch\/product\/1357923-ilaris-inj-los-150-mg-ml\/mpro [Accessed 21 May 2025]."},{"key":"2025052623151376000_15.5.e097981.22","unstructured":"Agency EM . Ilaris Product Information,"},{"key":"2025052623151376000_15.5.e097981.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"2025052623151376000_15.5.e097981.24","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.4.517"},{"key":"2025052623151376000_15.5.e097981.25","doi-asserted-by":"publisher","DOI":"10.3171\/2012.10.SPINE12727"},{"key":"2025052623151376000_15.5.e097981.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00586-015-4208-3"},{"key":"2025052623151376000_15.5.e097981.27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/acr.22392","article-title":"Clinically important changes in short form 36 health survey scales for use in rheumatoid arthritis clinical trials: the impact of low responsiveness","volume":"66","author":"Ward","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025052623151376000_15.5.e097981.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.06.022"},{"key":"2025052623151376000_15.5.e097981.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.06.009"},{"key":"2025052623151376000_15.5.e097981.30","unstructured":"R Foundation for Statistical Computing . A language and environment for statistical computing. Vienna, Austria, 2020."},{"key":"2025052623151376000_15.5.e097981.31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jclinepi.2018.11.001","article-title":"Marginal structural models and other analyses allow multiple estimates of treatment effects in randomized clinical trials: Meta-epidemiological analysis","volume":"107","author":"Ewald","year":"2019","journal-title":"J Clin Epidemiol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-097981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T06:15:44Z","timestamp":1748326544000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-097981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,26]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjopen-2024-097981"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-097981","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}